COVID-19 Impact on Gilead Sciences Inc
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Gilead Science Inc. performance.
Historically, Gilead Focused on Small Molecules for Anti-Viral Therapies.
Gilead’s Pipeline is Most Active in Early Stages of Drug Development.
Remdesivir Is the Main Focus of Attention Against COVID-19.
Gilead Acquires Forty Seven Inc. as a Continuation of Strategy to Diversify Pipeline Portfolio into Oncology.
Scope
This 32-page PowerPoint based report gives an important expert analysis on how C)VID-19 will affect Gilead Science Incorporated. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Reasons to Buy
An overview of how Gilead Sciences Inc. will be affected by the COVID-19 pandemic.
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.